Study designs for assessment of topical anti-inflammatory drugs in atopic dermatitis are discussed. Atopic dermatitis is a chronic disease with symmetrically distributed lesions. In order to avoid individual and spontaneous variation and to obtain an early impression of the efficacy of a new topical drug, bilaterally paired lesions can be used. Further drug development requires controlled double-blind parallel group design. General recommendations regarding inclusion criteria, and the measurement of efficacy and safety parameters are presented. Methods available for data evaluation and the particularities of different clinical designs are discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the effect of 2-borneol on the model through oxidative stress and acute toxicity tests.
Nat Prod Res
January 2025
Laboratory of Biology and Toxicology, Regional University of Cariri (URCA), Crato, Brazil.
Borneol, a compound found in resin-rich plants, is known for its aromatic and therapeutic properties. Widely used in countries, such as China, Japan, and Southeast Asia, borneol has also demonstrated efficacy in nanodrug administration. The primary objective of this study is to understand how borneol induces oxidative stress, its impact on the attraction and repulsion of , and its acute toxicity.
View Article and Find Full Text PDFFormulation, Characterization and in vitro Release of Topical Nanoemulsion Containing Prednisolone-Derived Corticosteroid.
Drug Dev Ind Pharm
January 2025
Ege University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Izmir, Turkey.
Backround: Prednisolone-Derived Corticosteroid (PDC), has anti-inflammatory activity in ocular administration. However, drug administration to the eye is extremely difficult due to the complex structure of the eye. Because of the ability of the eye to retain the drug and its physiology, the bioavailability of drugs applied to the eye is very low.
View Article and Find Full Text PDFEfficacy of a topical live probiotic in improving skin health.
Int J Cosmet Sci
January 2025
Blis Technologies Limited, Dunedin, New Zealand.
Introduction: Micrococcus luteus is a commensal bacterial member of the human skin and is essential in keeping the balance among the various microbial flora of the skin. M. luteus strain Q24 or BLIS Q24™ was isolated from the skin of a healthy human adult and is known to produce a unique antimicrobial spectrum that is inhibitory towards pathogens associated with skin diseases.
View Article and Find Full Text PDFFemtosecond laser-assisted large-diameter lamellar corneal-limbal keratoplasty in ocular chemical burns.
Am J Ophthalmol Case Rep
March 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Purpose: This study highlights the feasibility of femtosecond laser-assisted large-diameter lamellar corneal-limbal keratoplasty and its efficacy in the treatment of ocular surface failure caused by bilateral ocular chemical injury.
Observations: The series included 3 patients with ocular surface failure caused by bilateral ocular chemical burns. After dissection of the host cornea, a femtosecond laser-assisted large-diameter lamellar corneoscleral button, with varying thickness of 250-400 μm, was sutured to the recipient bed.
Travoprost Intracameral Implant in Eyes with Glaucoma or Ocular Hypertension: Early Short-Term Real-World Outcomes.
Clin Ophthalmol
January 2025
Harvard Eye Associates, Laguna Hills, CA, USA.
Purpose: To assess real-world efficacy and safety of standalone travoprost intracameral implant (iDose TR) implantation by a US glaucoma surgeon in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Methods: This non-randomized, retrospective, unmasked, consecutive case series included all cases of standalone iDose TR implantation from a single US glaucoma surgeon since the product's approval by the US Food and Drug Administration (FDA) in December 2023. Patients were pseudophakic, had OAG or OHT, and had undergone prior SLT and/or bimatoprost intracameral implant injection (Durysta).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!